3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Lung Neoplasms
5
Adenocarcinoma of Lung
3
Ovarian Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Salivary Gland Neoplasms
1
Recurrent Squamous Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Multiple Myeloma
1
MET Positive
1
Lymphoma, Non-Hodgkin
1
Head and Neck Neoplasms
1
Gliosarcoma
1
Glioblastoma
1
Central Nervous System Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma, Bronchiolo-Alveolar
1
Interventions
Etoposide
5
Rituximab
4
Radiotherapy
4
Methotrexate
4
Cytarabine
4
Cyclophosphamide
3
Cisplatin
3
Vincristine
2
Specimen Handling
2
Prednisone
2
Peripheral Blood Stem Cell Transplantation
2
Methylprednisolone
2
Gemcitabine
2
Fenretinide
2
Doxorubicin
2
Carmustine
2
venetoclax
1
tucatinib
1
temsirolimus
1
plerixafor
1
pertuzumab
1
palbociclib
1
olaparib
1
merphos
1
liposomal amphotericin B
1
ixabepilone
1
ibrutinib
1
ibritumomab tiuxetan
1
fludarabine
1
cobimetinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Lymphoma, Non-Hodgkin
×
Erlotinib Hydrochloride
×
Clear all
NCT03297606
2026-03-27
CAPTUR
Canadian Cancer Trials Group
Phase 2
Recruiting
720 enrolled